- Research article
- Open Access
- Open Peer Review
uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R
- Michaela C. Huber1,
- Rebecca Mall1,
- Herbert Braselmann2,
- Annette Feuchtinger3,
- Sara Molatore1,
- Katrin Lindner1,
- Axel Walch3,
- Eva Gross4,
- Manfred Schmitt5,
- Natalie Falkenberg†1 and
- Michaela Aubele†1Email author
© The Author(s). 2016
- Received: 20 January 2016
- Accepted: 3 August 2016
- Published: 8 August 2016
Due to lack of a targeted therapy for the triple-negative breast cancer (TNBC) patients, it is important to explore this aggressive breast cancer type in more detail and to establish novel therapeutic approaches. TNBC is defined negative for the protein expression of oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). One prominent feature of this cancer type is the frequent overexpression of major components of the urokinase-type plasminogen activator system (uPAS) including uPA, its receptor uPAR and the inhibitor PAI-1, which may be valuable as therapeutic targets.
Direct interactions of uPAR with interactors were demonstrated by immunoprecipitations and proximity ligation assays. For stable knockdowns of target proteins, lentiviral vectors were used and the effects were analysed by immunoblottings and using in vitro cell viability, migration and invasion assays. Immunohistochemical and statistical analyses of biomarkers and clinical parameters were conducted in a TNBC cohort (n = 174).
Direct tumour-promoting interactions of uPAR with uPA and the insulin-like growth factor receptor 1 (IGF1R) were shown in TNBC cells and these interactions were significantly reduced (p = 0.001) when uPAR was downregulated. The combined knockdown of uPAR and uPA or IGF1R additively and significantly reduced cell viability, migration and invasion of the model cell lines. In TNBC tissue, the complexes formed by uPAR with uPA or with IGF1R significantly correlated with the histological grade (p = 0.0019) as well as with cathepsin B and D (p ≤ 0.0001) that are implicated in cell invasion and metastasis.
Our outcomes show that not only overexpressed biomarkers promote tumourigenesis, but rather their interactions further potentiate tumour progression. This study emphasises the potential of combined approaches targeting uPAR and its interactors with regard to an improved therapy of TNBC.
- Prognostic impact
- uPAR interactome
- uPA system
In TNBC, there is a lack of protein expression of the oestrogen receptor (ER) and the progesterone receptor (PR) as well as a weak or absent protein expression of the human epidermal growth factor receptor 2 (HER2) . TNBC is the most aggressive tumour type among breast cancers that is associated with a poor prognosis and occurs in approximately 10 to 20 % of invasive breast cancers . Due to the lack of targeted therapies, the patients are treated systemically leading to severe side effects and besides that the therapy efficacy is limited; therefore novel therapeutic targets are strongly needed. Several research groups revealed insulin receptor (IR), insulin-like growth factor receptor 1 (IGF1R), epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (c-Met) and in particular the urokinase-type plasminogen activator (uPA) with its receptor (uPAR) to be overexpressed in many tumour entities including TNBC [3–9]. Except uPAR, these transmembrane receptors are activated by the binding of growth factors to their extracellular domain, followed by the formation of homo- and/or heterodimers, which induce phosphorylation of the intracellular receptor domains and recruit further signalling molecules to initiate signalling cascades within the cells [10, 11].
The receptors IR, IGF1R, EGFR and c-Met promote cell proliferation, invasion, survival and metastasis by activating the phosphatidylinositol 3-kinase (PI3K), Akt, mTOR pathway as well as the Ras, Raf, mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK) pathway and the signal transducer and activator of transcription (STAT) 3-mediated signalling [4, 12, 13]. uPAR is strongly involved in wound healing, clot lysis, tissue remodeling through binding to and activating pro-uPA, which in turn stimulates further invasion-promoting factors such as plasminogen and pro-matrixmetalloproteases (pro-MMPs) followed by the degradation of the extracellular matrix (ECM) leading to migration and invasion of tumour cells . It has been shown that strongly invasive TNBC cells and respective cell lines use this natural process and enhance their invasive capacity through overexpression of uPAR, uPA or MMPs [9, 15]. Depending on their cellular context and expression levels, IR, IGF1R, EGFR, c-Met and uPAR promote malignancy also through cooperating with each other and may be promising candidates for an improved cancer therapy . Since uPAR is solely associated to the plasma membrane by a glycosylphosphatidyl inositol (GPI) anchor, interactions with membrane-spanning receptors may enable uPAR-mediated intracellular signalling as well.
Considering IGF1R and IR inhibition, many attempts have been made with respect to targeted therapies, including several receptor tyrosine kinase inhibitors (RTKIs), monoclonal humanised antibodies or IGF-binding proteins . However, the therapeutic approach turned out to be less successful than expected. Due to high homology on DNA and protein level , a cross talk between IGF1R and IR signalling is supposed to diminish the inhibitory effects . Another challenge is the role of IR, which is significantly involved in glucose metabolism and therefore could not be completely blocked . EGFR-targeted therapeutic antibodies such as cetuximab or panitumumab or the TKIs gefitinib and erlotinib were applied in vitro and in clinical trials with TNBC patients indicating a successful therapy, however, mostly combinational approaches, also with chemotherapeutics, were more effective [17–22]. Anti-c-Met-based therapy using antibodies or tyrosine kinase inhibitors are currently tested in phase II clinical trials in TNBC patients [23–25]. Nevertheless, the success of RTKIs for cancer therapy is also limited due to intrinsic or acquired resistance by cancer cells .
In addition, therapeutic approaches have been made towards the uPA system (uPAS) components such as uPA, uPAR or PA inhibitor-1 (PAI-1). In particular in breast cancer, uPA and PAI-1 have been validated as predictive or prognostic biomarkers and in vivo experiments emphasise anti-tumour effects when uPA-uPAR interactions or uPA alone were inhibited [27–30]. uPAR was also knocked down in combination with the RNAi of uPA, HER2 or MMP9 or combined with Trastuzumab in different breast cancer cell lines and in in vivo studies resulting in reduced cell migration, invasion, angiogenesis or proliferation [31–33]. Co-overexpression of uPA, uPAR and IGF1R elevated the malignancy of pancreatic, hepatocellular, rhabdomyosarcoma, colon and breast cancer cells [6, 34–36].
To date, little is known regarding the role of uPAR and IGF1R in TNBC and whether these receptors directly interact with each other. In this study, to investigate in more detail the impact of these receptors in TNBC, uPAR, uPA and IGF1R were stably and simultaneously knocked down in two TNBC cell lines and the effects on in vitro cell migration, invasion, proliferation and on signalling molecules were examined. Furthermore, immunohistochemical analyses and PLA also using TNBC tissue samples (n = 174) demonstrate a direct interaction of uPAR with uPA and with IGF1R emphasizing additive effects of those interactions on TNBC tumour progression.
The following human breast cancer cells lines MDA-MB-361 (HTB-27), SKBR3 (HTB-30), T47D (HTB-133) were acquired from American Type Culture Collection (ATCC) and MCF7 (ACC115) cells from German Collection of Microorganisms and Cell Cultures, DSMZ). The BT549 and MDA-MB-231 cell lines are a kind gift from Prof. M. Schmitt, Clinical Research Unit, Department of Obstetrics and Gynecology, Technische Universität München). The BT549, T47D and MCF7 cells were maintained in RPMI 1640 with GlutaMAX (Rosewell Park Memorial Institute medium) supplemented with bovine insulin (10 μg/μl, Sigma, St. Lois, MO, USA). The SKBR3 and MDA-MB-361 cells were maintained in DMEM with GlutaMAX (Dulbecco Modified Eagles medium) that was additionally supplemented with non-essential amino acids (Life Technologies, Darmstadt, DE) for cultivation of MDA-MB-231 cells. Both media were supplemented with 10 % fetal calf serum (FCS, Invitrogen, Carlsbad, CA, USA) and 0.25 % of each penicillin and streptomycin (Life Technologies, Darmstadt, DE). The cells were maintained in a water humidified 37 °C incubator with 5 % CO2. The last cell line authentication was conducted before starting the experiments as described previously .
Lentiviral transductions of breast cancer cell lines
SMARTchoice™ lentiviral shRNA vectors (GE Healthcare Lafayette, CO, USA) were used for transductions for RNAi of uPAR (VSH6063, SH-006388-01, −02, −03), uPA (VSH6063, SH-006000-01, −02, −03), IGF1R (VSH6063, SH07-003012-04, −05, −06). For efficient knockdown of the target proteins, a pool of three viral particles (targeting three different fragments within the RNA sequence of the target protein), each at a multiplicity of infection (MOI) of 30, was used. All viral particles were tested for knockdown specificity and efficiency before starting the RNAi experiments. A total of 3.0 × 104 BT549 or MDA-MB-231 cells were seeded into each well of a 12-well plate and after 42 h infected with the lentiviral vectors for the knockdown of uPAR (uPAR_RNAi), of uPA (uPA_RNAi) and of IGF1R (IGF1R_RNAi). For a successful knockdown of the strongly overexpressed uPAR, respective infection was repeated several times as described . A vector containing a non-targeting sequence (SMARTvector 2.0 non-targeting particle) was used as negative control and a vector for GAPDH knockdown was used as positive control (SMARTvector 2.0 Human GAPD). For enhancing the infection, 2 μg/ml polybrene (Invitrogen, Carlsbad, CA, USA) was added to each approach as described . All infections were conducted in triplicates.
Quantitative reverse transcription-PCR (qRT-PCR)
The RNA isolation, TaqMan assays and analysis were conducted as described . Quantitative PCR was conducted in triplicates using TaqMan probes: uPAR (Hs00958880_m1), uPA (Hs01547054_m1) and IGF1R (Hs00609566_m1, Thermo Fisher, Waltham, Massachusetts, USA). The mRNA expression levels were calculated by the 2–ΔΔCT method and normalised to the control (HPRT1) and to MCF7 cells (calibrator).
Western blot analysis
The analysis and quantification of protein expressions or phosphorylations of uPAR , uPA, PAI-1, IGF1R, IR, c-Met, Paxillin, 44/42 MAPK, HER2, PR, ER, STAT3, p27Kip1, MMP2, MMP 9, GAPDH and Tubulin were analysed using primary antibodies (Additional file 1: Table S1) as described previously .
To determine potential interaction partners of uPAR, diverse immunoprecipitation protocols were established using the goat polyclonal anti-uPAR antibody (AF807, R&D Systems, Minneapolis, MN, USA) for 60 min at 4 °C based on previously described procedure . As negative control, a polyclonal goat isotype antibody was applied. The precipitated proteins were eluted with Laemmli buffer (2×) and further used for Western Blot analysis.
Wound scratch migration assay
To analyse the knockdown effects on in vitro cell migration, migration assays were conducted in six-well plates under serum-reduced conditions (0,1 % FBS) and the open areas were quantified using TScratch software as described . The migration assays were conducted in triplicates and the Student’s t-test was used for statistical analysis.
To analyse the knockdown effects on in vitro cell invasion, 2.0 × 104 control or infected BT549 or MDA-MB-231 cells were seeded in serum-reduced medium (0,1%FBS) in matrigel-coated chambers, inserted into 24-well cell culture plates and incubated for 48 h at 37 °C. The invasion assays were conducted according to manufacturers’ protocol and quantified by counting the invaded cells in 13 representative images. The invasion assays were conducted in triplicates and the means of each approach were quantified in relation to the mock control. The Student’s t-test was used for statistical analysis.
WST-1 cell proliferation assay
To analyse the knockdown effects on in vitro cell proliferation, 1.0 × 104 control or infected BT549 or MDA-MB-231 cells per well were seeded in a 96-well culture plate and the water soluble tetrazolium WST-1 assay (Roche Diagnostics, Mannheim, DE) was conducted in quintuplicate as described previously . The Student’s t-test was used for statistical analysis.
Generation of formalin-fixed and paraffin-embedded (FFPE) cell line blocks
To optimise the analysis of protein expressions and of protein complexes in cell lines and tumour samples, control and uPAR-depleted MDA-MB-231cell line blocks were generated as described previously .
Patients and tumour specimens
Formalin-fixed, paraffin-embedded breast cancer tissues of the TNBC type (n = 174) were collected at the Department of Gynecology and Obstetrics, Klinikum rechts der Isar, Technische Universität München, Germany. Written informed consent for the use of tissue samples for research purposes was obtained from all the patients. Approval for use of the tumour samples was given from the Ethics Committee of the Medical Faculty of the Technische Universität München, Germany.
The negative or only low protein expression of HER2 and of the steroid hormone receptors (ER, PR) in tumour tissues was verified by immunohistochemical analysis as described below. The other parameters of the 174 tumours are as following, in total, 90 tumours were node-negative. Concerning tumour size, 52 tumours were less than 2 cm, 93 were between 2 and 5 cm, and 29 tumours were more than 5 cm in size. The most tumours were classified as grade 3 (n = 150), followed by 21 cases as grade 2, and 3 cases as grade 1 . From 68 patients, data concerning breast cancer 1 mutation were available. The median follow-up of patients was 57 months (max. 244 months), with 52 (30 %) patients suffering from metastases within the period of clinical follow-up. All tumour patients were surgically treated and 108 of the patients received adjuvant chemotherapy.
Generation of tissue microarrays (TMAs)
TMAs were generated with a tissue-arraying instrument (Beecher Instruments Inc., Silver Spring, MD, USA) as described . Three micrometer thick sections were cut from the TMA blocks and both, the TMA and the punched block were re-examined to validate representative sampling.
Immunohistochemical (IHC) analysis
Immunohistochemical analysis was performed on 3 μm thick sections of the FFPE cell blocks and of tumour tissues using an automated stainer (Discovery XT) and a DAB Map kit (both Ventana Medical Systems, Tucson, AZ, USA) as described . The applied antibodies targeting uPAR, uPA, PAI-1, IGF1R, IR, c-Met, HER2, PR, ER, Plasminogen, Ki67, uPARAP, PTEN, p27Kip1, Cathepsin B and D are listed in Additional file 1: Table S1. The stained TMA specimens were assessed and scored by two independent observers using a 4-point scale (0–3+) .
Proximity ligation assay (PLA) technique on FFPE sections
For the visualisation of protein complexes with interaction partners of uPAR, the PLA technique was conducted on cell line blocks and on TMAs from tumour samples using the DUOLinkTM kit (OLINK, Uppsala, S) according to the manufacturer’s instruction as described [39, 47]. The primary antibodies targeting uPAR, uPA and IGF1R were the same, which were applied for IHC analysis. For the quantification of PLA, the slides were scanned and signals were evaluated as described previously . For each protein complex, signals of three visual fields per figure were calculated and subjected to statistical analysis.
Statistical analysis of tumour tissues
The correlations between experimental parameters and histopathological parameters were examined with Spearman’s rank correlation test. In all tests, statistical significance was considered when p ≤ 0.05.
uPAR, IGF1R and c-Met are significantly co-overexpressed in TNBC samples and breast cancer cell lines
The combined knockdown of uPAS components and of IGF1R significantly impairs tumour cell proliferation, migration and invasion in vitro
To investigate whether the knockdown of uPAS components and associated signalling proteins impairs the tumour progression of BT549 and MDA-MB-231 cells in vitro, uPAR, uPA and IGF1R were transiently downregulated, also in combination, in BT549 cells using several targeting and control small interfering RNAs (siRNAs, Additional file 2: Figure S1a and Additional file 3: Figure S2a). Transient RNAi of the target proteins and/or in combination significantly reduced in vitro cell viability, migration and invasion 48 h post-transfection (Additional file 2: Figure S1b-e and Additional file 3: Figure S2b-e). The expression of the invasion-promoting proteins MMP2, MMP9 or paxillin and the phosphorylation of STAT3 were reduced following uPAR RNAi alone or in combination with RNAi of uPA or IGF1R (Additional file 2: Figure S1b and Additional file 3: Figure S2b).
In MDA-MB-231 cells, RNAi of IGF1R or in combination with uPAR RNAi or uPA RNAi led to a strongly reduced phosphorylation of c-Met (Fig. 2a, left). In BT549 cells, the RNAi of IGF1R or combined with RNAi of uPAR or uPA led to a reduced phosphorylation of 44/42 MAPK (Fig. 2a, right). Following uPA RNAi or co-RNAi of uPA and IGF1R in BT549 cells, the MMP2 protein expression was diminished (Fig. 2a, right). In both cell lines, the cell cycle inhibitor p27Kip1 was induced following single IGF1R knockdown or combined with RNAi of uPA or uPAR (Fig. 2a), whereas no alteration on phosphorylation of STAT3 or Akt was observed (data not shown).
In comparison to the mock control, the cell proliferation was significantly (p ≤ 0.001) reduced in MDA-MB-231 cells following RNAi of IGF1R (−70 %) or uPA (−55 %) and following co-RNAi of uPAR and IGF1R (−65 %) or of uPA and IGF1R (−50 %) (Fig. 2b, left). In BT549 cells, compared to the mock control, only uPA-depleted cells showed a significantly reduced in vitro cell proliferation (−16 %, p = 0.003, Fig. 2b, right).
Furthermore, compared to MDA-MB-231 mock cells, the in vitro migration was significantly reduced following the RNAi of uPAR (−18 %, p < 0.001) and/or IGF1R (−25 %, p < 0.001, respectively) and uPA (−20 %, p = 0.002) (Fig. 2c, left, 24 h after starting the assay). More importantly, following co-RNAi of IGF1R and uPAR and compared to uPAR RNAi alone, the cell migration was additively and significantly reduced (−8 %, p = 0.027) as well as following co-RNAi of uPA and IGF1R compared to uPA RNAi alone (−8 %, p = 0.028) (Fig. 2c, left). Considering the effects 48 h after starting the in vitro migration assay and compared to the mock control, the RNAi of uPAR (−20 %, p = 0.003), of IGF1R (−25 %, p = 0.002) and of both receptors (−28 %, p = 0.027) or of IGF1R with uPA (−30 %, p < 0.001) significantly diminished the in vitro migration (Fig. 2c, right). Compared to BT549 mock control cells, the in vitro migration was significantly reduced following uPAR RNAi (−20 %, p = 0.001) or co-RNAi of uPA and IGF1R (−22 %, p = 0.001) as well as following co-RNAi of uPA and IGF1R (−22 %, p = 0.010) (Fig. 2c, right, 24 h after starting the assay). Compared to IGF1R RNAi alone, after the co-RNAi of uPAR and IGF1R (−16 %) the in vitro BT549 cell migration was additively reduced but not statistically significant (Fig. 2c, right, 24 h after starting the assay). Regarding the effects 48 h after starting the in vitro migration assay and compared to the mock control, the RNAi of uPA has a significant and reducing effect on in vitro BT549 cell migration (−15 %, p = 0.015), as well as the co-RNAi of IGF1R with uPAR or uPA (−28 % or −20 %, p = 0.001, respectively; Fig. 2c, right).
Concerning in vitro cell invasion, compared to MDA-MB-231 mock control cells, the RNAi of IGF1R significantly impaired cell invasion (−30 %, p = 0.006, Fig. 2d, left). Compared to RNAi of uPAR or IGF1R alone, the co-RNAi of uPAR and IGF1R significantly and additively reduced cell invasion (−65 % or −45 % respectively, p = 0.001) and showed the strongest effect of the analysed approaches (Fig. 2d, left). In BT549 cells, the in vitro cell invasion was not changed following RNAi of the target proteins or was elevated due to uPA RNAi (Fig. 2d, right).
In summary, the long-term RNAi of IGF1R and the combined RNAi with uPAR led to the most efficient reduction of in vitro proliferation, migration and invasion in both TNBC cell lines.
uPAR directly interacts with uPA and with IGF1R in vitro
uPAR directly interacts with uPA and with IGF1R in tumours and promotes the malignancy of TNBC
Significant protein expressions of uPAS components and tumour-associated markers
Tumour marker 1
Tumour marker 2
Significant correlations of uPAR/IGF1R or uPAR/uPA complexes with clinical parameters and tumour-associated markers
uPAR with IGF1R
uPAR with uPA
The triple-negative breast cancer mostly occurs in young women representing 10–20 % of breast cancers and shows an aggressive phenotype that is correlated with a poor prognosis . To date, these patients are systemically treated with chemo-/radiotherapy and surgery due to the lack of standard therapeutic targets in TNBC, such as ER, PR or HER2 in other breast cancer subtypes. Therefore, novel therapeutics and therapeutic strategies are urgently needed. Although TNBC is a heterogeneous disease , it is well known that the major components of the uPA system including uPA, uPAR and PAI-1 are often overexpressed in this BC subtype and may be interesting candidates for targeted therapies . Several tumour-promoting biomarkers such as EGFR, IGF1R, IR and c-Met are also co-overexpressed in TNBC [3, 4, 6–8]. The scope of this study was to demonstrate the potential of a long-term downregulation of uPAR combined with the downregulation of its already known and novel direct interaction partners. Based on preliminary results derived from transient knockdowns of uPAR, uPA and/or IGF1R leading to significantly reduced in vitro proliferation and metastasis, the long-term effects of uPAR- and IGF1R-RNAi were determined in two TNBC model cell lines after stable downregulations of 8 weeks. Since uPAR is associated to the cell membrane only by a GPI anchor, for intracellular signal transduction it has to interact with receptors containing a transmembrane domain. Since IGF1R is associated with uPAR [34, 35] and co-overexpressed in breast cancer [5, 6], here, it was downregulated in combination with uPAR and further analysed to demonstrate a direct interaction of both receptors. In comparison to single RNAi of the receptors, mostly the combined knockdown of uPAR and of IGF1R led to an additively and significantly impaired in vitro proliferation, migration and invasion, in particular of MDA-MB-231 cells. The knockdown of uPA alone or in combination with IGF1R RNAi also affected the malignant potential in vitro; however it was not as prominent as the combination of uPAR and IGF1R. Regarding the knockdown effects on the expression or phosphorylation of several tumour-associated proteins, the effects were rather minor. The phosphorylation of STAT3 or Akt was not changed following long-term knockdowns in both cell lines. Although the in vitro proliferation and metastasis was impaired, it is possible that after 8 weeks of downregulation, the cells adapt to or compensate the lack of uPAR, uPA and/or IGF1R and therefore, the effects on single proteins could not be detected anymore. Nevertheless, in MDA-MB-231 cells, a reduced phosphorylation of c-Met was observed, whereas the cell cycle inhibitor p27Kip1 was induced in both cell lines following IGF1R downregulation alone or in combination with uPA RNAi correlating with the results obtained from in vitro proliferation assays. Due to the lack of ER, PR and HER2 but strong uPAR protein expression and exhibiting an invasive phenotype, BT549 cells may be regarded as representative for TNBC. Concerning the protein expressions of IGF1R, MMPs or phosphorylation of c-Met, this cell line differs from MDA-MB-231 cells. In addition, the inhibitory knockdown effects in BT549 cells were not always comparable with those observed in MDA-MB-231 cells. However, our results are in agreement with previous studies demonstrating high molecular heterogeneity in TNBC and in numerous TNBC cell lines . Nevertheless, in BT549 cells, only the in vitro migration was significantly impaired due to RNAi of uPAR or co-RNAi of IGF1R with uPAR or uPA and this was confirmed by immunoblottings showing reduced activation of the metastasis marker MMP2. Neither comparable RNAi studies in BT549 cells nor the combined downregulation of uPAR with IGF1R in TNBC cell lines was demonstrated before. For knockdown studies simultaneously targeting uPAR, uPA or MMPs, mostly the MDA-MB-231, ZR751 or non-TNBC cell lines were applied and the combined knockdown approaches led to significant and additive effects regarding reduced malignancy of tumour cells [31–33] corresponding to our results. Furthermore, although the control shRNAs do not alter the RNA or protein levels of all the target proteins, the in vitro migration and invasion assays of the control approaches show in part unspecific results, which may be associated with the respective cell lines or in vitro assays. Thus, additional in vitro studies are necessary for understanding the tumourigenic signalling cascades in TNBC cells in more detail.
To further investigate the interactions of uPAR with several tumour-promoting proteins, uPA was confirmed and IGF1R was identified as direct interactor in the TNBC cohort and these complexes significantly correlated with cathepsin B and D, whereas IGF1R significantly correlated with cathepsin B and not with cathepsin D. Previous studies have shown cathepsins being correlated with uPAR or uPA and involved in metastasizing processes of breast cancer cells [15, 49] emphasizing the malignant potential of these interactions in TNBC. Furthermore, uPA expression alone significantly correlated with PAI-1, cathepsin D, plasminogen and Ki67 but not with the expression of uPAR, cathepsin B or other clinical parameters, whereas uPA-uPAR complexes significantly correlated with the expression of both cathepsins (B and D), IGF1R and inversely with the tumour size. For the latter correlation we hypothesise a metastasizing effect when the amount of uPAR-uPA complexes is elevated and tumour cells migrate and spread into different organs leading to cell loss within the primary tumour tissue and therefore to a reduced tumour size. IGF1R and uPAR complexes inversely correlated with uPA or PAI-1 expression. This outcome may result from competing impact on the binding site for IGF1R, uPA or PAI-1 with uPAR . The outcomes derived from PLA analyses and statistical correlations with tumour-relevant parameters indicate that not only the overexpression of tumour-promoting markers influences malignancy in TNBC but their interactions with other biomarkers may increase the malignant potential of tumour cells. The idea to impede the interactions of uPAR with uPA or IGF1R, as demonstrated by us, using the combined knockdown of the target proteins and leading to decreased malignancy in vitro may be thinkable for the future, to inhibit tumour progression in vivo by treating TNBC patients with inhibitors targeting these biomarkers in combination. However, further experiments including in vivo animal studies and clinical trials are necessary to endorse our hypothesis.
The overexpression of tumour-promoting biomarkers impacts malignancy in TNBC but their interactions with other signalling proteins may stronger influence the malignant potential of tumour cells. Impeding the complexes of uPAR with uPA or IGF1R may also strongly inhibit tumour progression in vivo by treating TNBC patients with inhibitors targeting these biomarkers in combination.
c-Met, hepatocyte growth factor receptor; ECM, extracellular matrix; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; ERK, extracellular signal-regulated kinase; GPI, glycosylphosphatidyl inositol; HER2, human epidermal growth factor receptor 2; IGF1R, insulin-like growth factor receptor 1; IHC, immunohistochemistry; IR, insulin receptor; MAPK, mitogen-activated protein kinase; MMP, matrixmetalloproteases; PI3K, phosphatidylinositol 3-kinase; PLA, proximity ligation assay; PR, progesterone receptor; RNAi, RNA interference; STAT, signal transducer and activator of transcription; TNBC, triple-negative breast cancer; uPA, urokinase-type plasminogen activator; uPAR, urokinase-type plasminogen activator
The authors thank John W.M. Martens for scanning the PLA signals of uPA-uPAR complexes and David Mörzl for excellent technical assistance.
This project was supported by the Wilhelm Sander-Stiftung, Munich, Germany, contract number 2012.028.1. to MA and MS.
Availability of data and material
The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.
MCH optimised methodologies, performed in vitro analyses, analysed and interpreted the data and drafted the manuscript. RM, SM, KL developed methodologies, conducted in vitro, immunohistochemical, PLA (proximity ligation assay) -analyses and analysed the data. AF, HB, EG, AW performed statistical analyses and interpreted the data. MS revised the manuscript, designed and supervised the study. NF and MA interpreted the data, drafted the manuscript, designed and supervised the study. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
Ethics approval and consent to participate
Written informed consent for the use of tissue samples for research purposes was obtained from all the patients. Approval for use of the tumour samples was given from the Ethics Committee of the Medical Faculty of the Technische Universität München, Germany.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Foulkes WD, Smith IE, Reis JS. Triple-negative breast cancer. New Engl J Med. 2010;363:1938–48.View ArticlePubMedGoogle Scholar
- Morris GJ, Naidu S, Topham AK, Guiles F, Xu YH, McCue P, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients - A single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results Database. Cancer. 2007;110:876–84.View ArticlePubMedGoogle Scholar
- Singh P, Alex JM, Bast F. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol. 2014;31:1.View ArticleGoogle Scholar
- Davison Z, de Blacquiere GE, Westley BR, May FEB. Insulin-like growth factor-dependent proliferation and survival of triple-negative breast cancer cells: implications for therapy. Neoplasia. 2011;13:504–15.View ArticlePubMedPubMed CentralGoogle Scholar
- Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu ZY, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367–74.View ArticlePubMedGoogle Scholar
- Nielsen TO, Andrews HN, Cheang M, Kucab JE, Hsu FD, Ragaz J, et al. Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: Potential for intervention with 17-allylamino geldanamycin. Cancer Res. 2004;64:286–91.View ArticlePubMedGoogle Scholar
- Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, et al. c-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005;113:678–82.View ArticlePubMedGoogle Scholar
- Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: Where are we? Int J Cancer. 2012;131:2471–77.View ArticlePubMedGoogle Scholar
- Foekens JA, Peters HA, Look MP, Portengen H, Schmitt M, Kramer MD, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000;60:636–43.PubMedGoogle Scholar
- Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer. 2006;13:S33–43.View ArticlePubMedGoogle Scholar
- Bonine-Summers AR, Aakre ME, Brown KA, Arteaga CL, Pietenpol JA, Moses HL, et al. Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells. Cancer Biol Ther. 2007;6:561–70.View ArticlePubMedPubMed CentralGoogle Scholar
- Law JH, Habibi G, Hu K, Masoudi H, Wang MYC, Stratford AL, et al. Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res. 2008;68:10238–46.View ArticlePubMedGoogle Scholar
- Meyer AS, Miller MA, Gertler FB, Lauffenburger DA. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Sci Signal. 2013;6:287.View ArticleGoogle Scholar
- Blasi F, Carmeliet P. uPAR: A versatile signalling orchestrator. Nat Rev Mol Cell Bio. 2002;3:932–43.View ArticleGoogle Scholar
- Duffy MJ, Duggan C, Maguire T, Mulcahy K, Elvin P, McDermott E, et al. Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. Enzyme Protein. 1996;49:85–93.PubMedGoogle Scholar
- Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986;5:2503–12.PubMedPubMed CentralGoogle Scholar
- Corkery B, Crown J, Clynes M, O’Donovan N. Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer. Ann Oncol. 2009;20:862–67.View ArticlePubMedGoogle Scholar
- Ferraro DA, Gaborit N, Maron R, Cohen-Dvashi H, Porat Z, Pareja F, et al. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR. Proc Natl Acad Sci U S A. 2013;110:1815–20.View ArticlePubMedPubMed CentralGoogle Scholar
- Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615–23.View ArticlePubMedPubMed CentralGoogle Scholar
- Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, et al. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact. Ann Oncol. 2014;25:1570–7.View ArticlePubMedGoogle Scholar
- Bernsdorf M, Ingvar C, Jorgensen L, Tuxen MK, Jakobsen EH, Saetersdal A, et al. Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial. Breast Cancer Res Treat. 2011;126:463–70.View ArticlePubMedGoogle Scholar
- Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, et al. Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer. Cancer Chemother Pharmacol. 2013;71:1183–90.View ArticlePubMedPubMed CentralGoogle Scholar
- Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, et al. Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies. J Clin Oncol. 2011;29:1271–79.View ArticlePubMedGoogle Scholar
- Yakes FM, Chen J, Tan J, Yamaguchi K, Shi YC, Yu PW, et al. Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth. Mol Cancer Ther. 2011;10:2298–308.View ArticlePubMedGoogle Scholar
- Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17.Google Scholar
- Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005;5:341–54.View ArticlePubMedGoogle Scholar
- Janicke F, Prechtl A, Thomssen C, Harbeck N, Meisner C, Untch M, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Nat Cancer Inst. 2001;93:913–20.View ArticlePubMedGoogle Scholar
- Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 8377 breast cancer patients. J Nat Cancer Inst. 2002;94:116–28.View ArticlePubMedGoogle Scholar
- Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, et al. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. 2000;14:1400–10.View ArticlePubMedGoogle Scholar
- Setyono-Han B, Sturzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, et al. Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UKI. Thromb Haemost. 2005;93:779–86.PubMedGoogle Scholar
- Subramanian R, Gondi CS, Lakka SS, Jutla A, Rao JS. siRNA-mediated simultaneous downregulation of uPA and its receptor inhibits angiogenesis and invasiveness triggering apoptosis in breast cancer cells. Int J Oncol. 2006;28:831–9.PubMedPubMed CentralGoogle Scholar
- Li CF, Cao S, Liu Z, Ye X, Chen LZ, Meng SD. RNAi-mediated downregulation of uPAR synergizes with targeting of HER2 through the ERK pathway in breast cancer cells. Int J Cancer. 2010;127:1507–16.View ArticlePubMedGoogle Scholar
- Kunigal S, Lakka SS, Good CS, Estes N, Rao JS. RNAi-mediated downregulation of urokinase plasminogen activator receptor and matrix metalloprotease-9 in human breast cancer cells results in decreased tumor invasion, angiogenesis and growth. Int J Cancer. 2007;121:2307–16.View ArticlePubMedPubMed CentralGoogle Scholar
- Bauer TW, Liu WB, Fan F, Camp ER, Yang A, Somcio RJ, et al. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-met- and insulin-like growth factor-1 receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res. 2005;65:7775–81.PubMedGoogle Scholar
- Bauer TW, Fan F, Liu WB, Johnson M, Parikh NU, Parry GC, et al. Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg. 2005;241:748–58.View ArticlePubMedPubMed CentralGoogle Scholar
- Gallicchio MA, Kaun C, Wojta J, Binder B, Bach LA. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. J Cell Physiol. 2003;197:131–8.View ArticlePubMedGoogle Scholar
- Ludyga N, Anastasov N, Rosemann M, Seiler J, Lohmann N, Braselmann H, et al. Effects of Simultaneous Knockdown of HER2 and PTK6 on Malignancy and Tumor Progression in Human Breast Cancer Cells. Mol Cancer Res. 2013;11:381–92.View ArticlePubMedGoogle Scholar
- D’Alessio S, Gerasi L, Blasi F. uPAR-deficient mouse keratinocytes fail to produce EGFR-dependent laminin-5, affecting migration in vivo and in vitro. J Cell Sci. 2008;121:3922–32.View ArticlePubMedGoogle Scholar
- Falkenberg N, Anastasov N, Hofig I, Bashkueva K, Lindner K, Hofler H, et al. Additive impact of HER2-/PTK6-RNAi on interactions with HER3 or IGF-1R leads to reduced breast cancer progression in vivo. Mol Oncol. 2015;9:282–94.View ArticlePubMedGoogle Scholar
- Falkenberg N, Anastasov N, Schaub A, Radulovic V, Schmitt M, Magdolen V, et al. Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221. Oncotarget. 2015;6:8103–14.View ArticlePubMedPubMed CentralGoogle Scholar
- Luther T, Magdolen V, Albrecht S, Kasper M, Riemer C, Kessler H, et al. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue. Am J Pathol. 1997;150:1231–44.PubMedPubMed CentralGoogle Scholar
- Ludyga N, Anastasov N, Gonzalez-Vasconcellos I, Ram M, Hofler H, Aubele M. Impact of protein tyrosine kinase 6 (PTK6) on human epidermal growth factor receptor (HER) signalling in breast cancer. Mol Biosyst. 2011;7:1603–12.View ArticlePubMedGoogle Scholar
- Molatore S, Kiermaier E, Jung CB, Lee M, Pulz E, Hofler H, et al. Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol Cancer. 2010;9:116.View ArticlePubMedPubMed CentralGoogle Scholar
- Ludyga N, Grunwald B, Azimzadeh O, Englert S, Hofler H, Tapio S, et al. Nucleic acids from long-term preserved FFPE tissues are suitable for downstream analyses. Virchows Arch. 2012;460:131–40.View ArticlePubMedGoogle Scholar
- Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.View ArticlePubMedGoogle Scholar
- Aubele M, Auer G, Walch AK, Munro A, Atkinson MJ, Braselmann H, et al. PTK (protein tyrosine kinase)-6 and HER2 and 4, but not HER1 and 3 predict long-term survival in breast carcinomas. Br J Cancer. 2007;96:801–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Aubele M, Spears M, Ludyga N, Braselmann H, Feuchtinger A, Taylor KJ, et al. In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues. Br J Cancer. 2010;103:663–7.View ArticlePubMedPubMed CentralGoogle Scholar
- Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.View ArticlePubMedPubMed CentralGoogle Scholar
- Maguire TM, Shering SG, Duggan CM, McDermott EW, O’Higgins NJ, Duffy MJ. High levels of cathepsin B predict poor outcome in patients with breast cancer. Int J Biol Markers. 1998;13:139–44.PubMedGoogle Scholar
- Wolff C, Malinowsky K, Berg D, Schragner K, Schuster T, Walch A, et al. Signalling networks associated with urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in breast cancer tissues: new insights from protein microarray analysis. J Pathol. 2011;223:54–63.View ArticlePubMedGoogle Scholar